Journal
JOURNAL OF INVESTIGATIVE DERMATOLOGY
Volume 134, Issue 2, Pages 441-451Publisher
ELSEVIER SCIENCE INC
DOI: 10.1038/jid.2013.340
Keywords
-
Categories
Funding
- The Israeli Centers for Research Excellence (I-CORE)
- Israel Cancer Association (ICA)
- Israel Cancer Research Fund (ICRF)
- US-Israel Binational Science Fund (BSF)
- Fritz Thyssen Stiftung
- Marie Curie Career Integration Grants (CIG)
- Dalya Gridinger Fund
- Fingerhot Carol
- Lionara Fund
- Shtacher Family Award
- Israel Cancer Research Fund
- Raymond and Beverly Sackler Chair in Bioinformatics
- Edmond J. Safra Center for Bioinformatics at Tel Aviv University
Ask authors/readers for more resources
Melanoma is one of the deadliest human cancers, responsible for approximately 80% of skin cancer mortalities. The aggressiveness of melanoma is due to its capacity to proliferate and rapidly invade surrounding tissues, leading to metastases. A recent model suggests melanoma progresses by reversibly switching between proliferation and invasion transcriptional signatures. Recent studies show that cancer cells are more sensitive to microRNA (miRNA) perturbation than are non-cancer cells; however, the roles of miRNAs in melanoma plasticity remain unexplored. Here, we use the gene expression profiles of melanoma and normal melanocytes to characterize the transcription factor miRNA relationship that modulates the proliferative and invasive programs of melanoma. We identified two sets of miRNAs that likely regulate these programs. Interestingly, one of the miRNAs involved in melanoma invasion is miR-211, a known target of the master regulator microphthalmia-associated transcription factor (MITF). We demonstrate that miR-211 contributes to melanoma adhesion by directly targeting a gene, NUAK1. Inhibition of miR-211 increases NUAK1 expression and decreases melanoma adhesion, whereas upregulation of miR-211 restores adhesion through NUAK1 repression. This study defines the MITF/miR-211 axis that inhibits the invasive program by blocking adhesion. Furthermore, we have identified NUAK1 as a potential target for the treatment of metastatic melanoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available